Ann: AVITA Medical Q4 2023 Investor Presentation, page-14

Thanks again @saltland. These recent posts show how good Hot Copper forums can be if people are willing to share their knowledge.

It looks like those pioneering surgeons using Recell and Novosorb together are breaking significant new ground in wound care. The surgeons' stories of patients being discharged in one-tenth of the normal hospital stay is outstanding and points to some huge cost savings which will support demand for these products.

There are also some other outstanding advantages which will drive demand, including much less infection and no rejection (unlike the commonly used animal-derived products) and reduction in scarring issues.

All of this is clearly pointing the way to a new standard of care in wound care. If this pans out as I expect over the next few years, then these two Australian companies stand to be great health-care success stories.